- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02361541
Determination of HCV Prevalence in a HIV Patient Cohort in Phnom Penh, Cambodia (HCV-Epi)
Determination of Hepatitis C Prevalence, Genetic Diversity and Treatment Eligibility in an HIV Patient Cohort in Phnom Penh, Cambodia
Hepatitis C (HCV) is an important global public health problem, disproportionately affecting HIV positive populations. Asia and Africa account for most of the co-infection burden, but access to HCV screening and treatment is still very limited. It is expected though, with the recent therapeutic advances and increasing global advocacy efforts, that HCV treatment should become a feasible option in the near future.
Sihanouk Hospital Center of HOPE (Phnom Penh, Cambodia) is catering for one of the largest HIV cohorts of the country, followed in an ambulatory settings. In this cohort, the prevalence of HCV co-infection will be determined, as well as HCV genotype diversity and the severity of liver disease. The researcher will also explore the performance of simple blood tests/panels as predictors of significant fibrosis and/or cirrhosis.
Patients will attend two study-visits. All adult patients of the HIV patient cohort of SHCH will be proposed HCV testing during their next HIV follow-up consultation, following the latest algorithm of the Centre for Disease Control (CDC) (May 2013). Anamnesis and clinical examination will focus, additionally to routine practice, on presence of general and HCV liver-disease related features. Laboratory analyses will include basic HIV tests (CD4), and tests for liver function such as Hepatitis B surface antigen (HbsAg) .
During the following routine HIV follow-up consultation, the results of HCV testing will be explained to the patient. If the patient is HCV negative, his/her study participation ends here. If currently infected with HCV, the clinician will repeat the HCV liver-disease (extra-hepatic & hepatic) related anamnesis and clinical examination, and prescribe additional blood tests for the non-invasive liver fibrosis/cirrhosis blood panel tests, liver and kidney function. Patients will moreover be asked to undergo a liver ultrasound and liver stiffness measurements.
Studienübersicht
Detaillierte Beschreibung
Hepatitis C (HCV) is an important global public health problem, disproportionally affecting HIV positive populations. Asia and Africa account for most of the co-infection burden, but access to HCV screening and treatment is still very limited. The high cost and complexity of current diagnostic and treatment algorithms are major bottlenecks and the linked lack of accurate HCV prevalence estimates and treatment-need data do not allow for robust treatment advocacy and program planning. Cambodia is not an exception.
It is expected though, with the recent therapeutic advances and increasing global advocacy efforts, that HCV treatment should become a feasible option in the near future. Sihanouk Hospital Center of HOPE (Phnom Penh, Cambodia) is catering for one of the largest HIV cohorts of the country, and it is planning to engage in HCV treatment from 2014 2015 onwards, with a double objective of direct patient benefit and catalyst role at national level, as in the past when starting its antiretroviral (ARV) program.
Within this specific setting, the researchers plan to determine the prevalence of HCV co-infection, HCV genotype diversity and severity of liver disease in this HIV patient cohort, followed in an ambulatory setting. The researchers will also explore the performance of simple blood tests/panels as predictors of significant fibrosis and/or cirrhosis .
The current HCV diagnostic procedures (and tools), as applied in this study, are too expensive and resource-demanding to allow for scalability in resource limited settings. Thus, the researchers plan to set up during this study a biobank with samples of a clinically well described HIV patient population. These samples should allow constituting a well-balanced panel for evaluation of future 'more scalable' HCV diagnostic tools.
Patients will attend two study-visits. All adult patients of the HIV cohort will be proposed HCV testing during their next regular HIV follow-up consultation. HCV testing will follow the latest algorithm of the Centre for Disease Control (CDC) (May 2013). During this same consultation, anamnesis and clinical examination will focus, additionally to routine practice ,on presence of general and HCV liver-disease related features. Laboratory analyses will also include basic HIV (CD4), and tests for liver function such as Hepatitis B surface antigen (HbsAg).
During the following routine HIV follow-up consultation (2-3 months later), the results of HCV testing will be explained to the patient. If the patient is HCV negative, his/her study participation ends here. If currently infected with Hepatitis C, the clinician will repeat the HCV liver-disease (extra-hepatic & hepatic) related anamnesis and clinical examination and prescribe additional blood tests for the non-invasive liver fibrosis/cirrhosis blood panel tests, liver and kidney function. Patients will moreover be asked to undergo a liver ultrasound and liver stiffness measurements.
The biobank will be set up with left over biological samples (whole blood plasma and serum) and comprehensive clinical information of all patients who give additional consent for this scope. Both biological samples and clinical information will be coded, to ensure confidentiality.
Studientyp
Einschreibung (Tatsächlich)
Kontakte und Standorte
Studienorte
-
-
-
Phnom Penh, Kambodscha
- Sihanouk Hospital Center of HOPE (SHCH), Cambodia
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Adult (> or = 18 years old)
- Documented HIV positive
- In regular HIV care follow-up (min. 2 consultations in the last six months prior to the study)
- Willing and able to provide written informed consent
Exclusion Criteria:
• HIV patients with currently taking Hepatitis C treatment or with a history of prior hepatitis C treatment
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
Intervention / Behandlung |
---|---|
HCV screening
All adult patients of an existing HIV cohort
|
HCV antibody screening, liver function tests, full blood count and HbsAg will performed.
Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping).
For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Seroprevalence of HCV infection
Zeitfenster: Baseline
|
Seroprevalence of HCV infection in the HIV patient cohort
|
Baseline
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
Proportion of current HCV infection
Zeitfenster: Baseline
|
Proportion of currently infected with HCV among the HCV-IgG positive HIV patients
|
Baseline
|
Proportion of HCV false-positives
Zeitfenster: Baseline
|
Proportion of HCV biologically false-positives among HCV-IgG positive screening
|
Baseline
|
HCV genotypes
Zeitfenster: Baseline
|
Proportions of different HCV genotypes
|
Baseline
|
Severity of liver disease in HCV patients
Zeitfenster: Baseline
|
To determine the severity of liver disease by transient elastography in this coinfected cohort
|
Baseline
|
HCV diagnostic accuracy
Zeitfenster: Baseline
|
To compare the diagnostic accuracy of commonly available blood panel tests for fibrosis staging in this coinfected cohort, with liver stiffness measurement (considered as reference standard).
|
Baseline
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Anja De Weggheleire, MD, Institute of Tropical Medicine, Antwerp, Belgium
- Hauptermittler: An Sokkab, MD, Sihanouk Hospital Center of HOPE (SHCH), Cambodia
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HCV-Epi
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Hepatitis C
-
Tripep ABInovio PharmaceuticalsUnbekanntChronische Hepatitis-C-VirusinfektionSchweden
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV) | Hepatitis-C-VirusinfektionVereinigte Staaten, Neuseeland
-
Trek Therapeutics, PBCAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 4 | Hepatitis-C-VirusinfektionVereinigte Staaten
-
Hadassah Medical OrganizationXTL BiopharmaceuticalsZurückgezogenChronische Hepatitis-C-VirusinfektionIsrael
-
Hadassah Medical OrganizationUnbekanntChronische Hepatitis-C-VirusinfektionIsrael
-
AbbVieAbgeschlossenHepatitis-C-Virus | Chronisches Hepatitis-C-Virus
-
AbbVieAbgeschlossenChronische Hepatitis C | Hepatitis C (HCV) | Hepatitis-C-Genotyp 1a
-
AbbVie (prior sponsor, Abbott)AbgeschlossenChronische Hepatitis C | Hepatitis-C-Genotyp 1 | Hepatitis C (HCV)Vereinigte Staaten, Australien, Kanada, Frankreich, Deutschland, Neuseeland, Puerto Rico, Spanien, Vereinigtes Königreich
-
ANRS, Emerging Infectious DiseasesUniversité Montpellier; Centre MurazAktiv, nicht rekrutierendChronische Hepatitis c | Hepatitis-C-Virusinfektion, Vergangenheit oder GegenwartBurkina Faso
-
Sohag UniversityRekrutierung
Klinische Studien zur HCV screening
-
University of La LagunaRekrutierung
-
University of La LagunaAbgeschlossenHepatitis-C-Virus-InfektionSpanien
-
Denver Health and Hospital AuthorityBoston University; Johns Hopkins University; Boston Medical Center; University of... und andere MitarbeiterAktiv, nicht rekrutierend
-
New York City Health and Hospitals CorporationAbgeschlossenHepatitis C | HIV/Aids | HIV | HCV-Koinfektion | HIV/AIDS und InfektionenVereinigte Staaten
-
ANRS, Emerging Infectious DiseasesAbgeschlossenDrogenkonsum | HCV-InfektionFrankreich
-
Hospital Universitario Infanta LeonorFundacion SEIMC-GESIDA; Instituto de Salud Carlos IIIAbgeschlossenHepatitis C | HIV | Schadensminimierung | Drogenkonsumenten
-
Centre hospitalier de l'Université de Montréal...Merck Sharp & Dohme LLC; Gilead Sciences; Ministere de la Sante et des Services...Abgeschlossen
-
Hasselt UniversityUnbekanntHepatitis C | DrogenkonsumBelgien
-
University of New MexicoBeendet
-
Asociación Colombiana de HepatologíaHospital Pablo Tobón UribeNoch keine RekrutierungHepatitis-C-Virus-InfektionKolumbien